+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Actinic keratosis - Pipeline Insight, 2024

  • PDF Icon

    Clinical Trials

  • 50 Pages
  • April 2024
  • Region: Global
  • DelveInsight
  • ID: 4330663
This “Actinic keratosis - Pipeline Insight, 2024,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Actinic keratosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Actinic keratosis Understanding

Actinic keratosis: Overview

Actinic keratoses are a premalignant squamous lesions. They may appear clinically as a erythematous, scaly macules or papules. Lesions typically present in middle aged or elderly patients. Sun exposed areas are most commonly affected. Squamous cell carcinoma may develop from preexisting actinic keratoses. Thus, biosy of suspected lesions and long term follow-up are necessary in patients with this condition. The risk of subsequent metastastatic dissemination is very low. The most likely factor that leads to the development of actinic keratosis is sunlight exposure, specifically UVA and UVB sunlight.[2] Exposure to these forms of radiation leads to a complex series of genetic events which eventually lead to the development of actinic keratosis and squamous cell carcinoma.

Actinic keratosis - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Actinic keratosis pipeline landscape is provided which includes the disease overview and Actinic keratosis treatment guidelines. The assessment part of the report embraces, in depth Actinic keratosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Actinic keratosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Actinic keratosis R&D. The therapies under development are focused on novel approaches to treat/improve Actinic keratosis.

Actinic keratosis Emerging Drugs Chapters

This segment of the Actinic keratosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Actinic keratosis Emerging Drugs

AVX001: Coegin Pharma AVX 001 is a small molecule compound that targets the group IVa phospholipase A2 (GIVa PLA2) enzyme being developed by Coegin Pharma. Currently, it is in Phase I/II stage of development to treatActinickeratosis.

VDA-1102: Vidac Pharma VDA-1102 ointment is the FIRST IN A NEW CLASS of drugs that selectively targets malignant cutaneous cells with minimal effects on surrounding healthy skin. VDA-1102 is an anti-neoplastic agent that utilizes a novel mechanism of action involving selective modulation of VDAC/HK2, a molecular system that is unique to glycolysis and mitochondrial function in cancer cells. This mechanism of action selectively triggers apoptosis in cancer cells with minimal effects on surroundingnormalcells.

Actinic keratosis: Therapeutic Assessment

This segment of the report provides insights about the different Actinic keratosis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Actinic keratosis

There are approx. 10+ key companies which are developing the therapies for Actinic keratosis. The companies which have their Actinic keratosis drug candidates in the most advanced stage, i.e. phase II include, VidacPharma.

Phases

This report covers around 10+ products under different phases of clinical development like
  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

Route of Administration

Actinic keratosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Oral
  • Parenteral
  • intravenous
  • Subcutaneous
  • Topical.

Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Actinic keratosis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Actinic keratosis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Actinic keratosis drugs.

Actinic keratosis Report Insights

  • Actinic keratosis Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Actinic keratosis Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Actinic keratosis drugs?
  • How many Actinic keratosis drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Actinic keratosis?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Actinic keratosis therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Actinic keratosis and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • VidacPharma
  • DFB Soria
  • G&E Herbal Biotechnology
  • Promius Pharma
  • DermAct Pharmaceutical
  • Sol-Gel Technologies
  • PROVECTUS BIOPHARMACEUTICALS
  • Coegin Pharma
  • Jupiter Wellness
  • MedC Biopharma Corporation

Key Products

  • VDA-1102
  • NanoPac
  • SR T100
  • DFD-07
  • AVX001
  • JW-200
  • MDC 2040
  • SGT 210


This product will be delivered within 2 business days.

Table of Contents

IntroductionExecutive Summary
Actinic keratosis: Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management
Pipeline Therapeutics
  • Comparative Analysis
Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type
Actinic keratosis - Analytical Perspective
Late Stage Products (Phase III)
  • Comparative Analysis
SR T100: G&E Herbal Biotechnology
  • Product Description
  • Research and Development
  • Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
  • Comparative Analysis
VDA-1102: VidacPharma
  • Product Description
  • Research and Development
  • Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase II)
  • Comparative Analysis
Drug name: Company name
  • Product Description
  • Research and Development
  • Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
  • Comparative Analysis
MDC 2040: MedC Biopharma Corporation
  • Product Description
  • Research and Development
  • Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
  • Comparative Analysis
Actinic keratosis Key CompaniesActinic keratosis Key ProductsActinic keratosis- Unmet NeedsActinic keratosis- Market Drivers and BarriersActinic keratosis- Future Perspectives and ConclusionActinic keratosis Analyst ViewsActinic keratosis Key CompaniesAppendixIntroductionExecutive Summary
Actinic keratosis: Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management
Pipeline Therapeutics
  • Comparative Analysis
Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type
Actinic keratosis - Analytical Perspective
Late Stage Products (Phase III)
  • Comparative Analysis
SR T100: G&E Herbal Biotechnology
  • Product Description
  • Research and Development
  • Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
  • Comparative Analysis
VDA-1102: VidacPharma
  • Product Description
  • Research and Development
  • Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase II)
  • Comparative Analysis
Drug name: Company name
  • Product Description
  • Research and Development
  • Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
  • Comparative Analysis
MDC 2040: MedC Biopharma Corporation
  • Product Description
  • Research and Development
  • Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
  • Comparative Analysis
Actinic keratosis Key CompaniesActinic keratosis Key ProductsActinic keratosis- Unmet NeedsActinic keratosis- Market Drivers and BarriersActinic keratosis- Future Perspectives and ConclusionActinic keratosis Analyst ViewsActinic keratosis Key CompaniesAppendix
List of Tables
Table 1 Total Products for Actinic keratosis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
List of Figures
Figure 1 Total Products for Actinic keratosis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • VidacPharma
  • DFB Soria
  • G&E Herbal Biotechnology
  • Promius Pharma
  • DermAct Pharmaceutical
  • Sol-Gel Technologies
  • PROVECTUS BIOPHARMACEUTICALS
  • Coegin Pharma
  • Jupiter Wellness
  • MedC Biopharma Corporation